Mga Batayang Estadistika
| CIK | 1763950 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Lantern Pharma Inc.
SEC Filings (Chronological Order)
Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.
| August 13, 2025 |
Lantern Pharma Reports Second Quarter 2025 Financial Results and Business Updates Exhibit 99.1 Lantern Pharma Reports Second Quarter 2025 Financial Results and Business Updates Major milestone achieved with successful completion of enrollment for LP-184 Phase 1a clinical trial, with 65 patients enrolled across a range of solid tumors including glioblastoma (GBM); LP-184 is a potential blockbuster drug-candidate with market potential of $10-12 billion USD in annual revenue. Maxi |
|
| August 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Lantern Pharma Inc. (Exact name of registrant as specified in its charter) Del |
|
| August 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 13, 2025 Lantern Pharma Inc. (Exact name of registrant as specified in its charter) Delaware 001-39318 46-3973463 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| August 8, 2025 |
United States Securities and Exchange Commission Washington, D.C. 20549 SCHEDULE 14A INFORMATION PROXY STATEMENT PURSUANT TO SECTION 14(A) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Pro |
|
| July 29, 2025 |
Exhibit 3.2 Amendment No. 2 to By-laws of Lantern Pharma Inc. (Adopted on July 24, 2025) Section 2.07 of the By-laws of Lantern Pharma Inc. is deleted in its entirety and replaced with the following: “Section 2.07 Quorum. Unless otherwise provided by law or the Corporation’s Certificate of Incorporation, one-third (33.33%) of the outstanding shares entitled to vote, present in person, by remote co |
|
| July 29, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 24, 2025 Lantern Pharma Inc. |
|
| July 28, 2025 |
United States Securities and Exchange Commission Washington, D.C. 20549 SCHEDULE 14A INFORMATION PROXY STATEMENT PURSUANT TO SECTION 14(A) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Pro |
|
| July 3, 2025 |
ATM Sales Agreement, dated July 3, 2025, by and between Lantern Pharma Inc. and ThinkEquity LLC Exhibit 1.1 LANTERN PHARMA INC. Up to $15,530,000 Shares of Common Stock ATM Sales Agreement July 3, 2025 ThinkEquity LLC 17 State Street, 41st Floor New York, New York 10004 Ladies and Gentlemen: Lantern Pharma Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with ThinkEquity LLC (the “Agent”), as follows: 1. Issuance and Sale of Shares. The Company agrees t |
|
| July 3, 2025 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 3, 2025 Lantern Pharma Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39318 46-3973463 (State or Other Jurisdiction of Incorporation) (Commission File N |
|
| July 3, 2025 |
ThinkEquity The date of this prospectus supplement is July 3, 2025. TABLE OF CONTENTS Filed Pursuant to Rule 424(b)(5) Registration No. 333-279718 PROSPECTUS SUPPLEMENT (To the Prospectus Dated June 10, 2024) Up to $15,530,000 of Shares of Common Stock Lantern Pharma Inc. We have entered into an ATM Sales Agreement, or the Sales Agreement, with ThinkEquity LLC, or ThinkEquity or the Sales Agent, relating to shares of our common stock, $0.0001 par value, or the Common Stock, offered |
|
| May 15, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Lantern Pharma Inc. (Exact name of registrant as specified in its charter) De |
|
| May 15, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 15, 2025 Lantern Pharma Inc. (Exact name of registrant as specified in its charter) Delaware 001-39318 46-3973463 (State or Other Jurisdiction of Incorporation) (Commission File N |
|
| May 15, 2025 |
Lantern Pharma Reports First Quarter 2025 Financial Results and Business Updates Exhibit 99.1 Lantern Pharma Reports First Quarter 2025 Financial Results and Business Updates ● Completion of LP-184 Phase 1a clinical trial enrollment with 62-65 patients across a range of solid tumors expected by end of June 2025. ● Additional patient data readout from the HARMONIC™ Trial evaluating LP-300 in never-smokers with non-small cell lung cancer (NSCLC) anticipated in Q3 2025, including |
|
| May 15, 2025 |
Exhibit 99.2 |
|
| April 30, 2025 |
Amendment to Employment Agreement with Panna Sharma dated December 28, 2023 Exhibit 10.18 FIFTH AMENDMENT TO EMPLOYMENT AGREEMENT This FIFTH AMENDMENT TO EMPLOYMENT AGREEMENT (this “Amendment”), is entered into as of December 28, 2023 and amends the Employment Agreement (defined below), between Lantern Pharma Inc. (the “Company”) and Panna Sharma (“Executive”). The Company and Executive may be referred to herein individually as a “Party” or collectively as the “Parties.” |
|
| April 30, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A Amendment No. 1 (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Lantern Pharma Inc. (Exact name of registrant as specified in it |
|
| March 27, 2025 |
Lantern Pharma Inc. Insider Trading Policy Exhibit 19.1 Lantern Pharma Inc. Policy on Insider Trading This Insider Trading Policy describes the standards of Lantern Pharma Inc., a Delaware corporation and its subsidiaries (the “Company”) on trading, and causing the trading of, the Company’s securities or securities of certain other publicly traded companies while in possession of confidential information. This Policy is divided into two pa |
|
| March 27, 2025 |
Amendment to Employment Agreement with Kishor Bhatia dated January 1, 2025 Exhibit 10.17 SEVENTH AMENDMENT TO EMPLOYMENT AGREEMENT This SEVENTH AMENDMENT TO EMPLOYMENT AGREEMENT (this “Amendment”), is entered into as of January 1, 2025 and amends the Employment Agreement (defined below), between Lantern Pharma Inc. (the “Company”) and Kishor G. Bhatia (“Executive”). The Company and Executive may be referred to herein individually as a “Party” or collectively as the “Part |
|
| March 27, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 27, 2025 Lantern Pharma Inc. |
|
| March 27, 2025 |
Lantern Pharma Provides Business Updates and Fourth Quarter & Year-End 2024 Financial Results Exhibit 99.1 Lantern Pharma Provides Business Updates and Fourth Quarter & Year-End 2024 Financial Results ● HARMONIC™ trial lead-in cohort delivered impressive 86% clinical benefit rate and 43% objective response rate in never-smoker NSCLC patients, with current expansion cohort reinforcing these positive trends as enrollment accelerates in Japan and Taiwan, where 33-40% of NSCLC cases occur in n |
|
| March 27, 2025 |
Exhibit 99.2 |
|
| March 27, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Lantern Pharma Inc. (Exact name of registrant as specified in its charter) Delawar |
|
| January 10, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 6, 2025 Lantern Pharma Inc. (Exact name of registrant as specified in its charter) Delaware 001-39318 46-3973463 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| November 8, 2024 |
Exhibit 99.1 |
|
| November 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 7, 2024 Lantern Pharma Inc. (Exact name of registrant as specified in its charter) Delaware 001-39318 46-3973463 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| November 7, 2024 |
Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 7, 2024 Lantern Pharma Inc. (Exact name of registrant as specified in its charter) Delaware 001-39318 46-3973463 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| November 7, 2024 |
Lantern Pharma Reports Third Quarter 2024 Financial Results and Business Updates Exhibit 99.1 Lantern Pharma Reports Third Quarter 2024 Financial Results and Business Updates ■ Lantern is advancing three AI-guided precision-oncology drug candidates in active Phase 1 and Phase 2 clinical trials, while evaluating additional ADC-based preclinical molecules for development. ■ Preliminary patient data and clinical readouts for the Phase 2 LP-300 Harmonic™ Trial showed an 86% clinic |
|
| November 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Lantern Pharma Inc. (Exact name of registrant as specified in its charter |
|
| August 8, 2024 |
Exhibit 99.3 |
|
| August 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Lantern Pharma Inc. (Exact name of registrant as specified in its charter) Del |
|
| August 8, 2024 |
Lantern Pharma Reports Second Quarter 2024 Financial Results and Business Updates Exhibit 99.1 Lantern Pharma Reports Second Quarter 2024 Financial Results and Business Updates ● Active clinical trials across three AI-guided drug candidates with additional ADC-based preclinical molecules in evaluation for development. ● Preliminary patient data and clinical readouts for Phase 2 LP-300 Harmonic™ Trial released showing an 86% clinical benefit rate in the initial 7 patient safety |
|
| August 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 8, 2024 Lantern Pharma Inc. (Exact name of registrant as specified in its charter) Delaware 001-39318 46-3973463 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| August 8, 2024 |
Exhibit 99.2 |
|
| June 17, 2024 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 13, 2024 Lantern Pharma Inc. (Exact name of registrant as specified in its charter) Delaware 001-39318 46-3973463 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| June 6, 2024 |
June 6, 2024 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Tyler Howes, Esq. Re: Lantern Pharma Inc. Registration Statement on Form S-3 File No. 333- 279718 Acceleration Request Requested Date: Monday, June 10, 2024 Requested Time: 4:30 p.m., Eastern Time. Ladies and Gentlemen: The undersigned registrant, Lantern P |
|
| May 24, 2024 |
Exhibit 3.2 Amendment No. 1 to By-laws of Lantern Pharma Inc. (Adopted on May 23, 2024) Section 3.02 of the By-laws of Lantern Pharma Inc. is deleted in its entirety and replaced with the following: “Section 3.02 Number; Term of Office. The Board of Directors shall consist of not less than three (3) and not more than nine (9) directors as fixed from time to time by resolution of the Board of Direc |
|
| May 24, 2024 |
As filed with the Securities and Exchange Commission on May 24, 2024 As filed with the Securities and Exchange Commission on May 24, 2024 Registration No. |
|
| May 24, 2024 |
As filed with the Securities and Exchange Commission on May 24, 2024 As filed with the Securities and Exchange Commission on May 24, 2024 Registration No. |
|
| May 24, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Lantern Pharma Inc. |
|
| May 24, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Lantern Pharma Inc. |
|
| May 24, 2024 |
Form of Subordinated Indenture Exhibit 4.3 LANTERN PHARMA INC. and Trustee INDENTURE Dated as of SUBORDINATED DEBT SECURITIES CROSS-REFERENCE TABLE(1) Section of Trust Indenture Act of 1939, as amended Section of Indenture 310(a) 6.09 310(b) 6.08 6.10 310(c) Inapplicable 311(a) 6.13 311(b) 6.13 311(c) Inapplicable 312(a) 4.01 4.04 312(b) 4.04(c) 312(c) 4.04(c) 313(a) 4.03 313(b) 4.03 313(c) 4.03 313(d) 4.03 314(a) 4.02 314(b) I |
|
| May 24, 2024 |
Exhibit 4.2 LANTERN PHARMA INC. and Trustee INDENTURE Dated as of SENIOR DEBT SECURITIES CROSS-REFERENCE TABLE(1) Section of Trust Indenture Act of 1939, as amended Section of Indenture 310(a) 6.09 310(b) 6.08 6.10 310(c) Inapplicable 311(a) 6.13 311(b) 6.13 311(c) Inapplicable 312(a) 4.01 4.04 312(b) 4.04(c) 312(c) 4.04(c) 313(a) 4.03 313(b) 4.03 313(c) 4.03 313(d) 4.03 314(a) 4.02 314(b) Inappli |
|
| May 24, 2024 |
Exhibit 4.4 Form of Senior Note (FACE OF SECURITY) [Each Global Security shall bear substantially the following legend: UNLESS AND UNTIL IT IS EXCHANGED IN WHOLE OR IN PART FOR SECURITIES IN DEFINITIVE REGISTERED FORM, THIS SECURITY MAY NOT BE TRANSFERRED EXCEPT AS A WHOLE BY THE DEPOSITARY TO A NOMINEE OF THE DEPOSITARY OR BY A NOMINEE OF THE DEPOSITARY TO THE DEPOSITARY OR ANOTHER NOMINEE OF THE |
|
| May 24, 2024 |
Exhibit 4.5 Form of Subordinated Note (FACE OF SECURITY) [Each Global Security shall bear substantially the following legend: UNLESS AND UNTIL IT IS EXCHANGED IN WHOLE OR IN PART FOR SECURITIES IN DEFINITIVE REGISTERED FORM, THIS SECURITY MAY NOT BE TRANSFERRED EXCEPT AS A WHOLE BY THE DEPOSITARY TO A NOMINEE OF THE DEPOSITARY OR BY A NOMINEE OF THE DEPOSITARY TO THE DEPOSITARY OR ANOTHER NOMINEE |
|
| May 24, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 23, 2024 Lantern Pharma Inc. |
|
| May 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 9, 2024 Lantern Pharma Inc. (Exact name of registrant as specified in its charter) Delaware 001-39318 46-3973463 (State or Other Jurisdiction of Incorporation) (Commission File Nu |
|
| May 9, 2024 |
Lantern Pharma Reports First Quarter 2024 Financial Results and Business Highlights Exhibit 99.1 Lantern Pharma Reports First Quarter 2024 Financial Results and Business Highlights ● Active clinical trials across three AI-guided drug candidates with initial data and clinical readouts for LP-184 on-track for the second half of 2024. ● Obtained regulatory allowance to begin Phase 2 Harmonic™ clinical trial enrollment in Japan and Taiwan where approximately 30-35+% of all lung cance |
|
| May 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Lantern Pharma Inc. (Exact name of registrant as specified in its charter) De |
|
| May 9, 2024 |
Exhibit 99.2 |
|
| April 29, 2024 |
United States Securities and Exchange Commission Washington, D.C. 20549 SCHEDULE 14A INFORMATION PROXY STATEMENT PURSUANT TO SECTION 14(A) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Pro |
|
| March 18, 2024 |
Amendment to Employment Agreement with David Margrave dated December 28, 2023 Exhibit 10.7 FOURTH AMENDMENT TO EMPLOYMENT AGREEMENT This FOURTH AMENDMENT TO EMPLOYMENT AGREEMENT (this “Amendment”), is entered into as of December 28, 2023 and amends the Employment Agreement (defined below), between Lantern Pharma Inc. (the “Company”) and David R. Margrave (“Executive”). The Company and Executive may be referred to herein individually as a “Party” or collectively as the “Part |
|
| March 18, 2024 |
(o) Lantern Pharma Inc. Executive Officer Clawback Policy Exhibit 97.1 LANTERN PHARMA INC. Executive Officer Clawback Policy Approved by the Board of Directors on November 27, 2023 (the “Adoption Date”) I. Purpose This Executive Officer Clawback Policy describes the circumstances under which Covered Persons of Lantern Pharma Inc., a Delaware corporation and any of its direct or indirect subsidiaries (the “Company”) will be required to repay or return Err |
|
| March 18, 2024 |
Amendment to Employment Agreement with Kishor Bhatia dated December 28, 2023 Exhibit 10.6 FIFTH AMENDMENT TO EMPLOYMENT AGREEMENT This FIFTH AMENDMENT TO EMPLOYMENT AGREEMENT (this “Amendment”), is entered into as of December 28, 2023 and amends the Employment Agreement (defined below), between Lantern Pharma Inc. (the “Company”) and Kishor G. Bhatia (“Executive”). The Company and Executive may be referred to herein individually as a “Party” or collectively as the “Parties |
|
| March 18, 2024 |
Exhibit 99.2 |
|
| March 18, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 18, 2024 Lantern Pharma Inc. (Exact name of registrant as specified in its charter) Delaware 001-39318 46-3973463 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| March 18, 2024 |
Lantern Pharma Reports Fourth Quarter & Fiscal Year 2023 Financial Results and Business Highlights Exhibit 99.1 Lantern Pharma Reports Fourth Quarter & Fiscal Year 2023 Financial Results and Business Highlights ● Multiple clinical trials across three AI-guided drug candidates are active with first expected data and readouts for LP-184 in the second half of 2024; with additional next-generation drug development programs approaching IND studies. ● Dosed initial patients in both Phase 1 clinical t |
|
| March 18, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Lantern Pharma Inc. (Exact name of registrant as specified in its charter) Delawar |
|
| March 1, 2024 |
LTRN / Lantern Pharma Inc. / Bios Equity Partners, LP - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 3)* Lantern Pharma Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 51654W101 (CUSIP Number) Bios Equity Partners, LP 1751 River Run, Suite 400 Fort Worth, Texas Tel: (817) 984-9197 With a Copy to: Rick Jordan Po |
|
| February 14, 2024 |
LTRN / Lantern Pharma Inc. / ProPhase Labs, Inc. Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A (Amendment No. 1) Under the Securities Exchange Act of 1934 Lantern Pharma Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 51654W101 (CUSIP Number) December 31, 2023 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the r |
|
| December 29, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 29, 2023 Lantern Pharma Inc. (Exact name of registrant as specified in its charter) Delaware 001-39318 46-3973463 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| December 1, 2023 |
LTRN / Lantern Pharma Inc / Bios Equity Partners, LP - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 2) Lantern Pharma Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 51654W101 (CUSIP Number) Bios Equity Partners, LP 1751 River Run, Suite 400 Fort Worth, Texas Tel: (817) 984-9197 With a Copy to: Rick Jordan Pol |
|
| November 24, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 21, 2023 Lantern Pharma Inc. |
|
| November 8, 2023 |
Exhibit 99.2 |
|
| November 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 8, 2023 Lantern Pharma Inc. (Exact name of registrant as specified in its charter) Delaware 001-39318 46-3973463 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| November 8, 2023 |
Lantern Pharma Reports Third Quarter 2023 Financial Results and Operational Highlights Exhibit 99.1 Lantern Pharma Reports Third Quarter 2023 Financial Results and Operational Highlights ● Received IND clearance from FDA to initiate Phase 1 clinical trial for LP-284, a first-in-human trial for advanced, refractory non-Hodgkin’s lymphomas (NHL). ● Dosed initial patient in Phase 1 with LP-184, a clinical trial for multiple advanced solid tumors that are refractory to standard-of-care |
|
| November 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Lantern Pharma Inc. (Exact name of registrant as specified in its charter |
|
| October 20, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 17, 2023 Lantern Pharma Inc. (Exact name of registrant as specified in its charter) Delaware 001-39318 46-3973463 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| August 9, 2023 |
Lantern Pharma Reports Second Quarter 2023 Financial Results and Operational Highlights Exhibit 99.1 Lantern Pharma Reports Second Quarter 2023 Financial Results and Operational Highlights ● Obtained FDA clearance of the IND application for LP-184 and activated initial clinical sites for the Phase 1 basket trial in relapsed/refractory advanced solid tumors and brain cancers - a patient population with unmet clinical needs. ● Completed IND-enabling studies for LP-284 and anticipate IN |
|
| August 9, 2023 |
Exhibit 99.2 |
|
| August 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 9, 2023 Lantern Pharma Inc. (Exact name of registrant as specified in its charter) Delaware 001-39318 46-3973463 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| August 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Lantern Pharma Inc. (Exact name of registrant as specified in its charter) Del |
|
| June 21, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 16, 2023 Lantern Pharma Inc. (Exact name of registrant as specified in its charter) Delaware 001-39318 46-3973463 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| May 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 9, 2023 Lantern Pharma Inc. (Exact name of registrant as specified in its charter) Delaware 001-39318 46-3973463 (State or Other Jurisdiction of Incorporation) (Commission File Nu |
|
| May 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Lantern Pharma Inc. (Exact name of registrant as specified in its charter) De |
|
| May 9, 2023 |
Exhibit 99.2 |
|
| May 9, 2023 |
Exhibit 10.1 FOURTH AMENDMENT TO EMPLOYMENT AGREEMENT This FOURTH AMENDMENT TO EMPLOYMENT AGREEMENT (this “Amendment”), is entered into as of January 1, 2023 and amends the Employment Agreement (defined below), between Lantern Pharma Inc. (the “Company”) and Kishor G. Bhatia (“Executive”). The Company and Executive may be referred to herein individually as a “Party” or collectively as the “Parties |
|
| May 9, 2023 |
Lantern Pharma Reports First Quarter 2023 Financial Results and Operational Highlights Exhibit 99.1 Lantern Pharma Reports First Quarter 2023 Financial Results and Operational Highlights ● Dosed first patient in the Phase 2 Harmonic™ clinical trial; a study for the unique population of non-small lung cancer patients who are never-smokers and who make up 15-20% of all lung cancer cases. ● Submission of the IND application for LP-184 to the US Food and Drug Administration (FDA) is ant |
|
| April 28, 2023 |
United States Securities and Exchange Commission Washington, D.C. 20549 SCHEDULE 14A INFORMATION PROXY STATEMENT PURSUANT TO SECTION 14(A) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Pro |
|
| March 20, 2023 |
Exhibit 21.1 List of Subsidiaries Name of Subsidiary Jurisdiction Starlight Therapeutics Inc. Delaware, USA Lantern Pharma Australia Pty Ltd Victoria, Australia Lantern Pharma Limited Northern Ireland |
|
| March 20, 2023 |
Exhibit 99.1 Lantern Pharma Reports Fourth Quarter and Fiscal Year 2022 Financial Results and Operational Highlights ● The Harmonic™ clinical trial, a Phase 2 study in never-smoker patients with non-small lung cancer, has activated 5 clinical trial sites, across 12 locations, and anticipates multiple additional sites in the US during the 1st half of 2023; first enrolled patients are anticipated fo |
|
| March 20, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Lantern Pharma Inc. (Exact name of registrant as specified in its charter) Delawar |
|
| March 20, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 20, 2023 Lantern Pharma Inc. (Exact name of registrant as specified in its charter) Delaware 001-39318 46-3973463 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| March 20, 2023 |
Second Amended and Restated 2018 Equity Incentive Plan dated October 20, 2022 Exhibit 10.1 SECOND AMENDED AND RESTATED LANTERN PHARMA INC. 2018 EQUITY INCENTIVE PLAN I. GENERAL PROVISIONS 1.1 Establishment. On August 29, 2018, the Board of Directors of Lantern Pharma Inc. adopted the Lantern Pharma Inc. 2018 Equity Incentive Plan. The Lantern Pharma Inc. 2018 Equity Incentive Plan was approved by the Lantern Pharma Inc. shareholders on August 29, 2018. On December 17, 2018, |
|
| March 20, 2023 |
Exhibit 99.2 |
|
| January 18, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 12, 2023 Lantern Pharma Inc. (Exact name of registrant as specified in its charter) Delaware 001-39318 46-3973463 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| November 21, 2022 |
LTRN / Lantern Pharma Inc. / ProPhase Labs, Inc. Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Amendment No. *) Under the Securities Exchange Act of 1934 Lantern Pharma Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 51654W101 (CUSIP Number) November 8, 2022 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule |
|
| November 7, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 7, 2022 Lantern Pharma Inc. (Exact name of registrant as specified in its charter) Delaware 001-39318 46-3973463 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| November 7, 2022 |
EXHIBIT 10.1 THIRD AMENDMENT TO EMPLOYMENT AGREEMENT This THIRD AMENDMENT TO EMPLOYMENT AGREEMENT (this ?Amendment?), is entered into as of August 1, 2022 and amends the Employment Agreement (defined below), between Lantern Pharma Inc. (the ?Company?) and Panna Sharma (?Executive?). The Company and Executive may be referred to herein individually as a ?Party? or collectively as the ?Parties.? RECI |
|
| November 7, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Lantern Pharma Inc. (Exact name of registrant as specified in its charter |
|
| November 7, 2022 |
Exhibit 99.2 |
|
| November 7, 2022 |
Lantern Pharma Reports Third Quarter 2022 Financial Results and Operational Highlights Exhibit 99.1 Lantern Pharma Reports Third Quarter 2022 Financial Results and Operational Highlights ? The Harmonic? clinical trial activated the first two clinical trial sites for a Phase 2 study in never-smoker patients with non-small lung cancer and anticipates multiple additional sites in the US during 2022 ? IND-enabling studies for both LP-184 and LP-284 are expected to be complete in Q1 2023 |
|
| August 8, 2022 |
Second Amendment, dated May 1, 2022, to Employment Agreement with David Margrave dated May 18, 2020. Exhibit 10.1 SECOND AMENDMENT TO EMPLOYMENT AGREEMENT This SECOND AMENDMENT TO EMPLOYMENT AGREEMENT (this ?Amendment?), is entered into as of May 1, 2022 and amends the Employment Agreement (defined below), between Lantern Pharma Inc. (the ?Company?) and David R. Margrave (?Executive?). The Company and Executive may be referred to herein individually as a ?Party? or collectively as the ?Parties.? |
|
| August 8, 2022 |
Lantern Pharma Reports Second Quarter 2022 Financial Results and Operational Highlights Exhibit 99.1 Lantern Pharma Reports Second Quarter 2022 Financial Results and Operational Highlights ? Lantern has launched the Phase 2 clinical trial, Harmonic?, for LP-300. The Harmonic? clinical trial is focused on never smokers with advanced non-small cell lung cancer (NSCLC) and will begin patient enrollment during Q3 2022. ? The IND applications for both LP-184 and LP-284 are being targeted |
|
| August 8, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 8, 2022 Lantern Pharma Inc. (Exact name of registrant as specified in its charter) Delaware 001-39318 46-3973463 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| August 8, 2022 |
Third Amendment, dated May 1, 2022, to Employment Agreement with Kishor Bhatia dated May 18, 2020 Exhibit 10.2 THIRD AMENDMENT TO EMPLOYMENT AGREEMENT This THIRD AMENDMENT TO EMPLOYMENT AGREEMENT (this ?Amendment?), is entered into as of May 1, 2022 and amends the Employment Agreement (defined below), between Lantern Pharma Inc. (the ?Company?) and Kishor G. Bhatia (?Executive?). The Company and Executive may be referred to herein individually as a ?Party? or collectively as the ?Parties.? REC |
|
| August 8, 2022 |
Exhibit 99.2 |
|
| August 8, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Lantern Pharma Inc. (Exact name of registrant as specified in its charter) Del |
|
| June 14, 2022 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 8, 2022 Lantern Pharma Inc. (Exact name of registrant as specified in its charter) Delaware 001-39318 46-3973463 (State or Other Jurisdiction of Incorporation) (Commission File N |
|
| May 3, 2022 |
DEFA14A 1 ea159332-defa14alantern.htm DEFINITIVE ADDITIONAL MATERIALS United States Securities and Exchange Commission Washington, D.C. 20549 SCHEDULE 14A INFORMATION PROXY STATEMENT PURSUANT TO SECTION 14(A) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. ) Filed by Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confident |
|
| May 3, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Lantern Pharma Inc. (Exact name of registrant as specified in its charter) De |
|
| May 3, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 3, 2022 Lantern Pharma Inc. (Exact name of registrant as specified in its charter) Delaware 001-39318 46-3973463 (State or Other Jurisdiction of Incorporation) (Commission File Nu |
|
| May 3, 2022 |
Exhibit 99.1 Lantern Pharma Reports First Quarter 2022 Financial Results and Operational Highlights ? RADR?, Lantern?s proprietary A.I. and machine learning platform, has now surpassed 20 billion data points, enhancing its precision, insights, and capabilities for oncology drug discovery ? Launch and enrollment of the HARMONIC? clinical trial expected in Summer of 2022; the Phase 2 trial is for LP |
|
| May 3, 2022 |
Exhibit 99.2 First Quarter 2022 Operating & Financial Results Conference Call / Webinar May 3 rd , 2022 4:30 PM Eastern Time NASDAQ :LTRN First Quarter 2022 Earnings 7KLVSUHVHQWDWLRQFRQWDLQVIRUZDUG ORRNLQJVWDWHPHQWVZLWKLQWKHPHDQLQJRI6HFWLRQ $RIWKH6HFXULWLHV$FWRI DVDPHQGHGDQG 6HFWLRQ (RIWKH6HFXULWLHV([FKDQJH$FWRI DVDPHQGHG7KHVHIRUZDUG ORRNLQJ |
|
| April 27, 2022 |
DEF 14A 1 ea158784-def14alantern.htm DEFINITIVE PROXY STATEMENT United States Securities and Exchange Commission Washington, D.C. 20549 SCHEDULE 14A INFORMATION PROXY STATEMENT PURSUANT TO SECTION 14(A) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Com |
|
| April 26, 2022 |
Exhibit 99.1 Lantern Pharma?s Board of Directors Names Maria Maccecchini, Ph.D. as a Director Nominee to Lantern?s Board of Directors DALLAS, April 26, 2022/PRNewswire/ - Lantern Pharma Inc. (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR? artificial intelligence (A.I.) and machine learning (ML) platform to transform the cost, pace, and timeline of oncology dr |
|
| April 26, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 20, 2022 Lantern Pharma Inc. (Exact name of registrant as specified in its charter) Delaware 001-39318 46-3973463 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| April 25, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 25, 2022 Lantern Pharma Inc. |
|
| March 22, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 22, 2022 Lantern Pharma Inc. (Exact name of registrant as specified in its charter) Delaware 001-39318 46-3973463 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| March 22, 2022 |
LTRN / Lantern Pharma Inc. / Bios Equity Partners, LP - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1) Lantern Pharma Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 51654W101 (CUSIP Number) Bios Equity Partners, LP 1751 River Run, Suite 400 Fort Worth, Texas Tel: (817) 984-9197 With a Copy to: Andrew Rosell W |
|
| March 22, 2022 |
Lantern Pharma Announces Extension of Existing Share Repurchase Program Exhibit 99.1 Lantern Pharma Announces Extension of Existing Share Repurchase Program DALLAS, March 22, 2022 /PRNewswire/ - Lantern Pharma Inc. (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR? artificial intelligence (?A.I.?) and machine learning (ML) platform to transform the cost, pace, and timeline of oncology drug discovery and development, today announced |
|
| March 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 10, 2022 Lantern Pharma Inc. (Exact name of registrant as specified in its charter) Delaware 001-39318 46-3973463 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| March 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Lantern Pharma Inc. (Exact name of registrant as specified in its charter) Delawar |
|
| March 10, 2022 |
EXHIBIT 21.1 List of Subsidiaries Name of Subsidiary Jurisdiction Lantern Pharma Australia Pty Ltd Victoria, Australia Lantern Pharma Limited Northern Ireland |
|
| March 10, 2022 |
Exhibit 99.2 NASDAQ:LTRN March 10 th , 2022 4:30 PM Eastern Time Fourth quarter 2021 Operating & Financial Results Conference Call / Webinar NASDAQ:LTRN TODAY?S SPEAKERS Panna Sharma Chief Financial Officer and Secretary Chief Scientific Officer Investor Relations Chief Executive Officer, President and Director David Margrave Dr. Kishor Bhatia Nicole Leber 1 NASDAQ:LTRN This presentation contains |
|
| March 10, 2022 |
Exhibit 99.1 Lantern Pharma Reports Fourth Quarter and Fiscal Year 2021 Financial Results and Operational Highlights ? RADR?, Lantern?s proprietary A.I. and machine learning platform, grew from 1.2 billion to over 18 billion data points, enhancing its precision, insights, and capabilities for oncology drug discovery ? Preparing for a 2022 launch of the Phase 2 trial for LP-300 in never smokers wit |
|
| January 24, 2022 |
Exhibit 99.1 Lantern Pharma Receives Rare Pediatric Disease and Orphan Drug Designations for LP-184 for the Treatment of Atypical Teratoid Rhabdoid Tumor (ATRT) ? an Aggressive and Rapidly Growing Form of Cancer of the Central Nervous System ? Designations reinforce unmet need for treatment options for patients, especially children with ATRT ? LP-184 for the potential treatment of ATRT is the thir |
|
| January 24, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 24, 2022 Lantern Pharma Inc. (Exact name of registrant as specified in its charter) Delaware 001-39318 46-3973463 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| January 11, 2022 |
LTRN / Lantern Pharma Inc. / Empery Asset Management, LP - LANTERN PHARMA INC. Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Lantern Pharma Inc. (Name of Issuer) Common Stock, par value $0.0001 (Title of Class of Securities) 51654W101 (CUSIP Number) December 31, 2021 (Date of event which requires filing of this statement) Check the appropriate box to designate the rule pursuant to which thi |
|
| November 22, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 22, 2021 Lantern Pharma Inc. (Exact name of registrant as specified in its charter) Delaware 001-39318 46-3973463 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| November 22, 2021 |
Lantern Pharma Announces Share Repurchase Program Exhibit 99.1 Lantern Pharma Announces Share Repurchase Program DALLAS, November 22, 2021 /PRNewswire/ - Lantern Pharma Inc. (NASDAQ: LTRN) (?Lantern? or the ?Company?), a clinical stage biopharmaceutical company using its proprietary RADR? artificial intelligence (?A.I.?) platform to transform the cost, pace, and timeline of oncology drug discovery and development, today announced that its board o |
|
| November 1, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Lantern Pharma Inc. (Exact name of registrant as specified in its charter |
|
| November 1, 2021 |
EX-99.2 2 ea149696ex99-2lantern.htm PRESENTATION RELATING TO NOVEMBER 1, 2021 CONFERENCE CALL AND LIVE WEBCAST TO DISCUSS FINANCIAL AND OPERATING RESULTS FOR QUARTER ENDED SEPTEMBER 30, 2021 Exhibit 99.2 November 1 st , 2021 4:30 PM Eastern Third quarter 2021 Operating & Financial Results Conference Call / Webinar TODAY’ S SPEAKERS Panna Sharma Chief Financial Officer and Secretary Chief Scientifi |
|
| November 1, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 1, 2021 Lantern Pharma Inc. (Exact name of registrant as specified in its charter) Delaware 001-39318 46-3973463 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| November 1, 2021 |
Lantern Pharma Reports Third Quarter 2021 Financial Results and Operating Highlights Exhibit 99.1 Lantern Pharma Reports Third Quarter 2021 Financial Results and Operating Highlights - RADR? A.I. platform surpasses 10 billion datapoints, significantly enhancing speed and scope of new drug development and expanding potential for biopharma collaborations - Drug candidate LP-184 granted Orphan Drug Designations by the FDA for the treatment of glioblastoma multiforme and pancreatic ca |
|
| July 29, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Lantern Pharma Inc. (Exact name of registrant as specified in its charter) Del |
|
| July 29, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 29, 2021 Lantern Pharma Inc. (Exact name of registrant as specified in its charter) Delaware 001-39318 46-3973463 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| July 29, 2021 |
Lantern Pharma Reports Second Quarter 2021 Financial Results and Operational Highlights Exhibit 99.1 Lantern Pharma Reports Second Quarter 2021 Financial Results and Operational Highlights ? Obtained positive preclinical data in pancreatic cancer showing a significant reduction, averaging 93%, in tumor volume in in-vivo animal models from research collaboration with Fox Chase Cancer Center ? Preparing clinical trial site selection and finalization of initial GMP drug material batch d |
|
| July 29, 2021 |
Exhibit 99.2 Second Quarter 2021 Operating & Financial Results Conference Call July 29, 2021 4:30 PM Eastern https://ir.lanternpharma.com/ FORWARD - LOOKING STATEMENTS This presentation contains forward - looking statements within the meaning of Section 27 A of the Securities Act of 1933 , as amended, and Section 21 E of the Securities Exchange Act of 1934 , as amended . These forward - looking st |
|
| July 8, 2021 |
July 8, 2021 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Irene Paik, Esq. Re: Lantern Pharma Inc. Registration Statement on Form S-3 File No. 333-257643 Acceleration Request Requested Date: Monday, July 12, 2021 Requested Time: 5:00 p.m., Eastern Time. Ladies and Gentlemen: The undersigned registrant, Lantern Pha |
|
| July 2, 2021 |
Exhibit 4.5 Form of Subordinated Note (FACE OF SECURITY) [Each Global Security shall bear substantially the following legend: UNLESS AND UNTIL IT IS EXCHANGED IN WHOLE OR IN PART FOR SECURITIES IN DEFINITIVE REGISTERED FORM, THIS SECURITY MAY NOT BE TRANSFERRED EXCEPT AS A WHOLE BY THE DEPOSITARY TO A NOMINEE OF THE DEPOSITARY OR BY A NOMINEE OF THE DEPOSITARY TO THE DEPOSITARY OR ANOTHER NOMINEE |
|
| July 2, 2021 |
Exhibit 4.4 Form of Senior Note (FACE OF SECURITY) [Each Global Security shall bear substantially the following legend: UNLESS AND UNTIL IT IS EXCHANGED IN WHOLE OR IN PART FOR SECURITIES IN DEFINITIVE REGISTERED FORM, THIS SECURITY MAY NOT BE TRANSFERRED EXCEPT AS A WHOLE BY THE DEPOSITARY TO A NOMINEE OF THE DEPOSITARY OR BY A NOMINEE OF THE DEPOSITARY TO THE DEPOSITARY OR ANOTHER NOMINEE OF THE |
|
| July 2, 2021 |
Form of Subordinated Indenture Exhibit 4.3 LANTERN PHARMA INC. and Trustee INDENTURE Dated as of SUBORDINATED DEBT SECURITIES CROSS-REFERENCE TABLE(1) Section of Trust Indenture Act of 1939, as amended Section of Indenture 310(a) 6.09 310(b) 6.08 6.10 310(c) Inapplicable 311(a) 6.13 311(b) 6.13 311(c) Inapplicable 312(a) 4.01 4.04 312(b) 4.04(c) 312(c) 4.04(c) 313(a) 4.03 313(b) 4.03 313(c) 4.03 313(d) 4.03 314(a) 4.02 314(b) I |
|
| July 2, 2021 |
As filed with the Securities and Exchange Commission on July 2, 2021 As filed with the Securities and Exchange Commission on July 2, 2021 Registration No. |
|
| July 2, 2021 |
Exhibit 4.2 LANTERN PHARMA INC. and Trustee INDENTURE Dated as of SENIOR DEBT SECURITIES CROSS-REFERENCE TABLE(1) Section of Trust Indenture Act of 1939, as amended Section of Indenture 310(a) 6.09 310(b) 6.08 6.10 310(c) Inapplicable 311(a) 6.13 311(b) 6.13 311(c) Inapplicable 312(a) 4.01 4.04 312(b) 4.04(c) 312(c) 4.04(c) 313(a) 4.03 313(b) 4.03 313(c) 4.03 313(d) 4.03 314(a) 4.02 314(b) Inappli |
|
| May 25, 2021 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 19, 2021 Lantern Pharma Inc. (Exact name of registrant as specified in its charter) Delaware 001-39318 46-3973463 (State or Other Jurisdiction of Incorporation) (Commission File N |
|
| May 3, 2021 |
Quarterly Report - QUARTERLY REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Lantern Pharma Inc. (Exact name of registrant as specified in its charter) De |
|
| May 3, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 3, 2021 Lantern Pharma Inc. (Exact name of registrant as specified in its charter) Delaware 001-39318 46-3973463 (State or Other Jurisdiction of Incorporation) (Commission File Nu |
|
| May 3, 2021 |
EX-99.2 3 ea140232ex99-2lanternpharma.htm PRESENTATION RELATING TO MAY 3, 2021 CONFERENCE CALL AND LIVE WEBCAST TO DISCUSS FINANCIAL AND OPERATING RESULTS FOR QUARTER ENDED MARCH 31, 2021 Exhibit 99.2 First Quarter 2021 Operating & Financial Results Conference Call May 3, 2021 4:30 PM Eastern https://ir.lanternpharma.com/ FORWARD - LOOKING STATEMENTS This presentation contains forward - looking st |
|
| May 3, 2021 |
Lantern Pharma Reports First Quarter 2021 Financial Results and Operational Highlights Exhibit 99.1 Lantern Pharma Reports First Quarter 2021 Financial Results and Operational Highlights ? RADR? A.I. platform surpasses 4.6 billion datapoints curated for oncology drug development across a wide a range of tumors and drug classes ? Phase 2 clinical trial for non-smokers with NSCLC (Non-Small Cell Lung Cancer) utilizing LP-300 in combination with chemotherapy scheduled to begin during t |
|
| April 9, 2021 |
United States Securities and Exchange Commission Washington, D.C. 20549 SCHEDULE 14A INFORMATION PROXY STATEMENT PURSUANT TO SECTION 14(A) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by Registrant S Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) S Definitive Pro |
|
| April 9, 2021 |
- DEFINITIVE ADDITIONAL MATERIALS UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A INFORMATION PROXY STATEMENT PURSUANT TO SECTION 14(A) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Pro |
|
| March 10, 2021 |
Amendment to Employment Agreement dated February 18, 2021 with Kishor G. Bhatia EX-10.17 3 f10k2020ex10-17lantern.htm AMENDMENT TO EMPLOYMENT AGREEMENT DATED FEBRUARY 18, 2021 WITH KISHOR G. BHATIA Exhibit 10.17 AMENDMENT TO EMPLOYMENT AGREEMENT This AMENDMENT TO EMPLOYMENT AGREEMENT (this “Amendment”), is entered into as of March 4, 2021 and amends the Employment Agreement, dated as of June 16, 2020 (the “Employment Agreement”), between Lantern Pharma Inc. (the “Company”) an |
|
| March 10, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Lantern Pharma Inc. (Exact name of registrant as specified in its charter) Delawar |
|
| March 10, 2021 |
EX-4.3 2 f10k2020ex4-3lantern.htm DESCRIPTION OF CAPITAL STOCK Exhibit 4.3 DESCRIPTION OF CAPITAL STOCK Lantern Pharma (“Company”, “we”, “us” and “our”) has one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended, namely our common stock, par value $0.0001 per share. The following is a summary of the rights of our common and of certain provisions of o |
|
| March 10, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 10, 2021 Lantern Pharma Inc. (Exact name of registrant as specified in its charter) Delaware 001-39318 46-3973463 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| March 10, 2021 |
EX-99.2 3 ea137363ex99-2lanternpharma.htm PRESENTATION RELATING TO MARCH 10, 2021 CONFERENCE CALL AND LIVE WEBCAST TO DISCUSS FINANCIAL AND OPERATING RESULTS FOR FISCAL YEAR AND QUARTER ENDED DECEMBER 31, 2020 Exhibit 99.2 Fourth Quarter and Fiscal Year End 2020 Operating & Financial Results Conference Call March 10, 2021 4 PM Eastern https://ir.lanternpharma.com/ FORWARD - LOOKING STATEMENTS This |
|
| March 10, 2021 |
Lantern Pharma Reports Fourth Quarter and Year End 2020 Financial Results and Operational Highlights Exhibit 99.1 Lantern Pharma Reports Fourth Quarter and Year End 2020 Financial Results and Operational Highlights ? RADR? artificial intelligence (?A.I.?) platform surpassed 1.2 billion datapoints ? Advanced opportunities for LP-184 in glioblastoma, prostate and pancreatic cancers in collaboration with leading cancer research centers ? Identified and validated additional genomically-driven cancer |
|
| February 16, 2021 |
SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G (Amendment No. )* Under the Securities Exchange Act of 1934 Lantern Pharma Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 51654W101 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which th |
|
| February 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Amendment # LANTERN PHARMA Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 51654W101 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule purs |
|
| January 25, 2021 |
JOINT ACQUISITION STATEMENT PURSUANT TO RULE 13d-1(k) SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Lantern Pharma Inc. (Name of Issuer) Common Stock, par value $0.0001 (Title of Class of Securities) 51654W101 (CUSIP Number) January 14, 2021 (Date of event which requires filing of this statement) Check the appropriate box to designate the rule pursuant to which this |
|
| January 15, 2021 |
Filed pursuant to Rule 424(b)(4) Registration Nos. 333-251992 and 333-252116 PROSPECTUS 4,285,715 Shares Common Stock Lantern Pharma Inc. We are offering 4,285,715 shares of our common stock on a firm commitment basis. Our common stock is listed on the Nasdaq Capital Market under the symbol “LTRN” and, on January 14, 2021, the last reported sale price of our common stock on the Nasdaq Capital Mark |
|
| January 15, 2021 |
As publicly filed with the Securities and Exchange Commission on January 15, 2021 Registration No. |
|
| January 11, 2021 |
ThinkEquity A division of Fordham Financial Management, Inc. 17 State Street, 22nd Floor New York, NY 10004 January 11, 2021 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporate Finance 100 F St., NE Washington, D.C. 20549 Re: Lantern Pharma Inc. Registration Statement on Form S-1 Ladies and Gentlemen: Pursuant to Rule 461 of the General Rules and Regulations of the U.S. Securit |
|
| January 11, 2021 |
Filed Pursuant to Rule 433 Registration Statement No. 333-251992 Issuer Free Writing Prospectus dated January 11, 2021 Relating to Preliminary Prospectus dated January 8, 2021 Nasdaq: LTRN 1 Lantern Pharma Company Overview January 11, 2021 Leveraging A.I., Machine Learning & Genomics to Rescue, Repurpose and Develop Targeted Cancer Therapies Filed Pursuant to Rule 433 Registration Statement No. 33 |
|
| January 8, 2021 |
Registration Statement - REGISTRATION STATEMENT As publicly filed with the Securities and Exchange Commission on January 8, 2021 Registration No. |
|
| January 8, 2021 |
January 8, 2021 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Alan Campbell, Esq. Re: Lantern Pharma Inc. Registration Statement on Form S-1 Acceleration Request Requested Date: Wednesday, January 13, 2021 Requested Time: 5:00 p.m., Eastern Standard Time. Ladies and Gentlemen: In accordance with Rule 461 under the |
|
| January 8, 2021 |
Second Addendum to Technology License Agreement dated December 30, 2020 with AF Chemicals, LLC EX-10.16 4 ea132545ex10-16lanternpharm.htm SECOND ADDENDUM TO TECHNOLOGY LICENSE AGREEMENT DATED DECEMBER 30, 2020 WITH AF CHEMICALS, LLC Exhibit 10.16 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (i) NOT MATERIAL AND (ii) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE AND CONFIDENTIAL. SECOND ADDENDUM TO TECHNOLOGY LICENSE AG |
|
| January 8, 2021 |
Form of Underwriting Agreement Exhibit 1.1 UNDERWRITING AGREEMENT between LANTERN PHARMA INC and THINKEQUITY A DIVISION OF FORDHAM FINANCIAL MANAGEMENT, INC. as Representative of the Several Underwriters LANTERN PHARMA INC. UNDERWRITING AGREEMENT New York, New York [●] 2021 ThinkEquity A Division of Fordham Financial Management, Inc. As Representative of the several Underwriters named on Schedule 1 attached hereto 17 State Stre |
|
| January 6, 2021 |
Entry into a Material Definitive Agreement, Other Events - CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 30, 2020 Lantern Pharma Inc. (Exact name of registrant as specified in its charter) Delaware 001-39318 46-3973463 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| December 16, 2020 |
As confidentially submitted to the Securities and Exchange Commission on December 16, 2020 As confidentially submitted to the Securities and Exchange Commission on December 16, 2020 Registration No. |
|
| December 15, 2020 |
Lantern Pharma Inc. 1920 McKinney Avenue, 7th Floor Dallas, Texas 75201 December 16, 2020 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Lantern Pharma Inc. Draft Registration Statement on Form S-1 Confidentially Submitted: December 16, 2020 Ladies and Gentlemen: In connection with confidential submission of a Draft R |
|
| October 29, 2020 |
Exhibit 99.2 Third Quarter 2020 Operating & Financial Results Conference Call OCTOBER 29, 2020 4 PM Eastern https://ir.lanternpharma.com/ FORWARD - LOOKING STATEMENTS This presentation contains forward - looking statements within the meaning of Section 27 A of the Securities Act of 1933 , as amended, and Section 21 E of the Securities Exchange Act of 1934 , as amended . These forward - looking sta |
|
| October 29, 2020 |
Quarterly Report - QUARTERLY REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Lantern Pharma Inc. (Exact name of registrant as specified in its charter |
|
| October 29, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 29, 2020 Lantern Pharma Inc. (Exact name of registrant as specified in its charter) Delaware 001-39318 46-3973463 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| October 29, 2020 |
API Services Project Agreement dated July 10, 2020 with Patheon API Service Exhibit 10.1 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (i) NOT MATERIAL AND (ii) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. [***] Lantern Pharma ProjectConfidential Page 2 of 27 Patheon API Services, Inc. (“Patheon”) Patheon API Services, Inc. (“Patheon”) 101 Technology Place Florence, SC 29501 101 Technology Place |
|
| October 29, 2020 |
Lantern Pharma Reports Third Quarter 2020 Financial Results & Continued Operational Progress Exhibit 99.1 Lantern Pharma Reports Third Quarter 2020 Financial Results & Continued Operational Progress ● Surpassed One Billion Curated Data Points Powering Company’s Proprietary A.I. Platform, RADR®, for Cancer Drug Development ● Advanced LP-184 as a Potential Treatment for Glioblastoma, by Confirming its Ability to Effectively Penetrate the Blood Brain Barrier (BBB) in a 3D Model ● Accelerated |
|
| August 21, 2020 |
AMENDED AND RESTATED LANTERN PHARMA INC. 2018 EQUITY INCENTIVE PLAN I. GENERAL PROVISIONS Exhibit 99.1 AMENDED AND RESTATED LANTERN PHARMA INC. 2018 EQUITY INCENTIVE PLAN I. GENERAL PROVISIONS 1.1 Establishment. On August 29, 2018, the Board of Directors of Lantern Pharma Inc. adopted the Lantern Pharma Inc. 2018 Equity Incentive Plan. The Lantern Pharma Inc. 2018 Equity Incentive Plan was approved by the Lantern Pharma Inc. shareholders on August 29, 2018. On December 17, 2018, the Bo |
|
| August 21, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 19, 2020 Lantern Pharma Inc. (Exact name of registrant as specified in its charter) Delaware 001-39318 46-3973463 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| July 30, 2020 |
Exhibit 99.2 https://ir.lanternpharma.com/ FORWARD - LOOKING STATEMENTS This presentation contains forward - looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward - looking statements include, among other things, statements relating to: future events or our future financial pe |
|
| July 30, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 30, 2020 Lantern Pharma Inc. (Exact name of registrant as specified in its charter) Delaware 001-39318 46-3973463 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| July 30, 2020 |
Exhibit 99.1 Lantern Pharma Reports Second Quarter 2020 Financial Results and Continued Corporate Progress Closed Initial Public Offering Raising Gross Proceeds of $26.3 Million Surpassed 500 Million Curated Oncology Data Points for Company’s RADR® A.I. Platform Advanced Manufacturing Capabilities for LP-300 and LP-184 Trials DALLAS, TX – JULY 30, 2020 – Lantern Pharma (NASDAQ: LTRN), a clinical s |
|
| July 30, 2020 |
Quarterly Report - QUARTERLY REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Lantern Pharma Inc. (Exact name of registrant as specified in its charter) Del |
|
| July 16, 2020 |
Entry into a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 10, 2020 Lantern Pharma Inc. (Exact name of registrant as specified in its charter) Delaware 001-39318 46-3973463 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| June 23, 2020 |
EX-99.J EXHIBIT J June 10, 2020 Leslie W. Kreis, Jr. 1751 River Run, Suite 400 Fort Worth, Texas 76107 Re: Transfer of Securities Issued Under any Options or Other Awards Received as Compensation for Services Rendered as a Director of Lantern Pharma Inc. Mr. Kreis: This letter agreement (this “Agreement”) serves to confirm the agreement by and between Leslie W. Kreis, Jr., an individual resident o |
|
| June 23, 2020 |
LANTERN PHARMA INC. AMENDED AND RESTATED 2018 EQUITY INCENTIVE PLAN Notice of Stock Option Grant EX-99.I 4 d949930dex99i.htm EX-99.I EXHIBIT I LANTERN PHARMA INC. AMENDED AND RESTATED 2018 EQUITY INCENTIVE PLAN Notice of Stock Option Grant The Participant has been granted the following Stock Option (the “Option”) to purchase Shares of the Common Stock of Lantern Pharma Inc. (the “Corporation”): Name of Participant: Leslie W. Kreis, Jr. Total Number of Option Shares: 9,135 Type of Option: ☒ No |
|
| June 23, 2020 |
LANTERN PHARMA INC. 2018 EQUITY INCENTIVE PLAN Notice of Stock Option Grant EX-99.B 3 d949930dex99b.htm EX-99.B EXHIBIT B LANTERN PHARMA INC. 2018 EQUITY INCENTIVE PLAN Notice of Stock Option Grant The Participant has been granted the following Stock Option (the “Option”) to purchase Shares of the Common Stock of Lantern Pharma Inc. (the “Corporation”): Name of Participant: Bios Directors, LP Total Number of Option Shares: Type of Option: ☒ Nonqualified Stock Option or ☐ |
|
| June 23, 2020 |
Lock-Up Agreement, Biological Mimetics, Inc. dated May 14, 2020 EXHIBIT 1 LOCK-UP AGREEMENT, BMI DATED MAY 14, 2020 Lock-Up Agreement May 14, 2020 ThinkEquity A Division of Fordham Financial Management, Inc. |
|
| June 23, 2020 |
JOINT FILING AGREEMENT PURSUANT TO RULE 13d-1(k) EX-99.A 2 d949930dex99a.htm EX-99.A EXHIBIT A JOINT FILING AGREEMENT PURSUANT TO RULE 13d-1(k) The undersigned acknowledge and agree that the foregoing statement on Schedule 13D is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13D shall be filed on behalf of each of the undersigned without the necessity of filing additional joint filing |
|
| June 23, 2020 |
EXHIBIT 3 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, the undersigned hereby acknowledge and agree that the foregoing statement on Schedule 13D is filed on behalf of each of the undersigned and that all subsequent amendments to this statement shall be filed on behalf of each of the undersigned without the necessity of filing additional joint filing agreements. |
|
| June 23, 2020 |
LTRN / Lantern Pharma Inc. / BIOLOGICAL MIMETICS INC - SCHEDULE 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. ) LANTERN PHARMA INC. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 51654W 101 (CUSIP Number) David S. Silberstein Biological Mimetics, Inc. 124 Byte Drive Frederick, Maryland 21702 (301) 471 0201 (Name, Address an |
|
| June 23, 2020 |
LTRN / Lantern Pharma Inc. / Bios Equity Partners, LP - SC 13D Activist Investment SC 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 Lantern Pharma Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 51654W101 (CUSIP Number) Bios Equity Partners, LP 1751 River Run, Suite 400 Fort Worth, Texas Tel: (817) 984-9197 With a Copy to: Andrew Rosell Winstead PC |
|
| June 23, 2020 |
Lock-Up Agreement, David Silberstein dated May 15, 2020 EXHIBIT 2 LOCK-UP AGREEMENT, DAVID S. SILBERSTEIN DATED MAY 15, 2020 Lock-Up Agreement May 15, 2020 ThinkEquity A Division of Fordham Financial Management, Inc. 17 State Street, 22nd Floor New York, NY 10004 As Representative of the several Underwriters named on Schedule 1 to the Underwriting Agreement referenced below Ladies and Gentlemen: The undersigned understands that ThinkEquity, a Division |
|
| June 19, 2020 |
Amendment to Employment Agreement dated May 18, 2020 with Panna Sharma. EX-99.2 3 ea123226ex99-2lantern.htm AMENDMENT TO EMPLOYMENT AGREEMENT DATED MAY 18, 2020 WITH PANNA SHARMA Exhibit 2 AMENDMENT TO EMPLOYMENT AGREEMENT This AMENDMENT TO EMPLOYMENT AGRREEMENT amends the Employment Agreement, dated as of the 23rd day of July, 2018 (the “Employment Agreement”), between Lantern Pharma Inc. (the “Company”), and Panna Sharma (“Executive”) is entered into as of May 18, 2 |
|
| June 19, 2020 |
Lock up Agreement dated May 20, 2020. Exhibit 1 Lock-Up Agreement May 20, 2020 ThinkEquity A Division of Fordham Financial Management, Inc. |
|
| June 19, 2020 |
LTRN / Lantern Pharma Inc. / SHARMA PANNA - SCHEDULE 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. ) LANTERN PHARMA INC. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 51654W 101 (CUSIP Number) Panna Sharma President and Chief Executive Officer Lantern Pharma Inc. 1920 McKinney Avenue, 7th Floor Dallas, Texas 752 |
|
| June 17, 2020 |
EX-99.1 4 ea123112ex99-1lantern.htm PRESS RELEASE ANNOUNCING THE CLOSING OF THE INITIAL PUBLIC OFFERING Exhibit 99.1 FOR IMMEDIATE RELEASE Monday, June 15, 2020 Lantern Pharma Announces Closing of Initial Public Offering DALLAS, TX / June 15, 2020 / Lantern Pharma Inc. (LTRN) (the “Company”), a clinical stage biotechnology company, focused on leveraging artificial intelligence (“A.I.”), machine le |
|
| June 17, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 11, 2020 Lantern Pharma Inc. (Exact name of registrant as specified in its charter) Delaware 001-39318 46-3973463 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| June 17, 2020 |
Amended and Restated Certificate of Incorporation Exhibit 3.1(v) |
|
| June 17, 2020 |
Certificate of Amendment to Certificate of Incorporation Exhibit 3.1(iv) |
|
| June 12, 2020 |
Filed Pursuant to Rule 424(b)(4) Registration Nos. 333-237714 and 333-239112 1,750,000 Shares Common Stock Lantern Pharma Inc. This is a firm commitment initial public offering of common stock of Lantern Pharma Inc. Prior to this offering, there has been no public market for our common stock. We are offering 1,750,000 shares of our common stock at an initial public offering price of $15.00. Our co |
|
| June 12, 2020 |
As filed with the Securities and Exchange Commission on June 12, 2020 Registration No. |
|
| June 8, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 Lantern Pharma Inc. (Exact name of registrant as specified in its charter) Delaware 46-3973463 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification Number) |
|
| June 8, 2020 |
June 8, 2020 VIA EDGAR United States Securities and Exchange Commission 100 F Street, N. |
|
| June 8, 2020 |
Amendment to Employment Agreement dated May 18, 2020 with Panna Sharma Exhibit 10.3 AMENDMENT TO EMPLOYMENT AGREEMENT This AMENDMENT TO EMPLOYMENT AGRREEMENT amends the Employment Agreement, dated as of the 23rd day of July, 2018 (the “Employment Agreement”), between Lantern Pharma Inc. (the “Company”), and Panna Sharma (“Executive”) is entered into as of May 18, 2020, and will become effective upon the Company’s initial public offering (“IPO”) and listing of its com |
|
| June 8, 2020 |
ThinkEquity A division of Fordham Financial Management, Inc. 17 State Street, 22nd Floor New York, NY 10004 June 8, 2020 VIA EDGAR U.S. Securities and Exchange Commission 100 F St., NE Washington, D.C. 20549 Re: Lantern Pharma Inc. Registration Statement on Form S-1, as amended (File No. 333-237714) Ladies and Gentlemen: Pursuant to Rule 461 of the General Rules and Regulations of the U.S. Securit |
|
| June 8, 2020 |
As filed with the Securities and Exchange Commission on June 8, 2020 Registration No. |
|
| June 2, 2020 |
Scott E. Bartel 633 West 5th Street, Suite 4000 Los Angeles, California 90071 [email protected] Direct: 213.358.6174 June 2, 2020 Ms. Sasha Parikh Ms. Vanessa Robertson Ms. Irene Paik Mr. Jeffrey Gabor Division of Corporation Finance Office of Life Sciences Securities and Exchange Commission 100 F Street, NE Washington, D.C. 20549 Re: Lantern Pharma Inc. Amendment No. 2 to Registratio |
|
| May 22, 2020 |
Scott E. Bartel 633 West 5th Street, Suite 4000 Los Angeles, California 90071 [email protected] Direct: 213.358.6174 May 22, 2020 Ms. Sasha Parikh Ms. Vanessa Robertson Ms. Irene Paik Mr. Jeffrey Gabor Division of Corporation Finance Office of Life Sciences Securities and Exchange Commission 100 F Street, NE Washington, D.C. 20549 Re: Lantern Pharma Inc. Amendment No. 2 to Registratio |
|
| May 19, 2020 |
Employment Agreement dated May 18, 2020 with Kishor G Bhatia Exhibit 10.16 EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (this “Agreement”), is made and entered into to be effective as of first day of business after the closing of the I.P.O. (defined below) (the “Effective Date”), between Lantern Pharma Inc. (the “Company”), and KISHOR G. BHATIA (“Executive”). The Company and Executive may be referred to herein individually as a “Party” or collectively as |
|
| May 19, 2020 |
Form of Certificate of Amendment to the Certificate of Incorporation EX-3.1(IV) 3 ea122016ex3-1ivlantern.htm FORM OF CERTIFICATE OF AMENDMENT TO THE CERTIFICATE OF INCORPORATION Exhibit 3.1.(iv) FORM OF CERTIFICATE OF AMENDMENT TO CERTIFICATE OF INCORPORATION OF LANTERN PHARMA INC. Lantern Pharma Inc., a corporation organized and existing under the laws of the State of Delaware (hereinafter called the “Corporation”), does hereby certify as follows: FIRST: That this |
|
| May 19, 2020 |
As filed with the Securities and Exchange Commission on May 19, 2020 Registration No. |
|
| May 19, 2020 |
Filed Pursuant to Rule 433 of the Securities Act of 1933 Issuer Free Writing Prospectus dated May 19, 2020 Relating to Preliminary Prospectus dated May 19, 2020 Registration No. |
|
| May 19, 2020 |
EX-10.15 8 ea122016ex10-15lantern.htm FORM OF LOCK-UP AGREEMENT Exhibit 10.15 Lock-Up Agreement May 13, 2020 ThinkEquity A Division of Fordham Financial Management, Inc. 17 State Street, 22nd Floor New York, NY 10004 As Representative of the several Underwriters named on Schedule 1 to the Underwriting Agreement referenced below Ladies and Gentlemen: The undersigned understands that ThinkEquity, a |
|
| May 19, 2020 |
Form of Underwriters’ Warrant (2020) Exhibit 1.1 UNDERWRITING AGREEMENT between LANTERN PHARMA INC and THINKEQUITY A DIVISION OF FORDHAM FINANCIAL MANAGEMENT, INC. as Representative of the Several Underwriters LANTERN PHARMA INC. UNDERWRITING AGREEMENT New York, New York [●], 2020 ThinkEquity A Division of Fordham Financial Management, Inc. As Representative of the several Underwriters named on Schedule 1 attached hereto 17 State Str |
|
| May 19, 2020 |
Form of Amended and Restated Certificate of Incorporation Exhibit 3.1.(v) FORM OF AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF LANTERN PHARMA INC. (Pursuant to Sections 242 and 245 of the General Corporation Law of the State of Delaware) Lantern Pharma Inc., a corporation organized and existing under the laws of the State of Delaware, hereby certifies as follows: FIRST: The present name of the corporation is Lantern Pharma Inc. and the date of fi |
|
| May 19, 2020 |
Employment Agreement dated May 18, 2020 with Kishor G Bhatia EX-10.3 6 ea122016ex10-3lantern.htm AMENDMENT TO EMPLOYMENT AGREEMENT DATED MAY 18, 2020 WITH PANNA SHARMA Exhibit 10.3 AMENDMENT TO EMPLOYMENT AGREEMENT This AMENDMENT TO EMPLOYMENT AGRREEMENT amends the Employment Agreement, dated as of the 23rd day of July, 2018 (the “Employment Agreement”), between Lantern Pharma Inc. (the “Company”), and Panna Sharma (“Executive”) is entered into as of May 18 |
|
| May 19, 2020 |
Form of Amendment to Series A Preferred Stock Warrant Exhibit 4.1.(iv) LANTERN PHARMA INC. Form of Amendment to Preferred Stock Warrant Original Date of Issuance: This Amendment to Preferred Stock Warrant, dated as of 2020 (“Amendment”), by and between Lantern Pharma Inc., a Delaware corporation (the “Issuer”), and (“Holder”). RECITALS WHEREAS, the Issuer issued that certain Preferred Stock Warrant (“Warrant ”) to the Holder on the Original Date of I |
|
| May 19, 2020 |
Employment Agreement dated May 18, 2020 with David Margrave EX-10.4 7 ea122016ex10-4lantern.htm EMPLOYMENT AGREEMENT DATED MAY 18, 2020 WITH DAVID MARGRAVE Exhibit 10.4 EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (this “Agreement”), is made and entered into to be effective as of first day of business after the closing of the I.P.O. (defined below) (the “Effective Date”), between Lantern Pharma Inc., a Delaware corporation (the “Company”), and David R. M |
|
| May 12, 2020 |
Specimen Stock Certificate evidencing shares of common stock Exhibit 4.2 |
|
| May 12, 2020 |
As filed with the Securities and Exchange Commission on May 12, 2020 Registration No. |
|
| May 12, 2020 |
Scott E. Bartel 633 West 5th Street, Suite 4000 Los Angeles, California 90071 [email protected] Direct: 213.358.6174 May 11, 2020 Ms. Sasha Parikh Ms. Vanessa Robertson Ms. Irene Paik Mr. Jeffrey Gabor Division of Corporation Finance Office of Life Sciences Securities and Exchange Commission 100 F Street, NE Washington, D.C. 20549 Re: Lantern Pharma Inc. Registration Statement on Form |
|
| April 16, 2020 |
Addendum to Drug License and Development Agreement with Oncology Venture A/S dated February 8, 2016 Exhibit 10.9 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (i) NOT MATERIAL AND (ii) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. FINAL VERSION 2/8/16 CONFIDENTIAL ADDENDUM TO DRUG LICENSE AND DEVELOPMENT AGREEMENT by and between LANTERN PHARMA, INC. and ONCOLOGY VENTURE, APS FINAL VERSION 2/8/16 CONFIDENTIAL ADDENDUM TO |
|
| April 16, 2020 |
Exhibit 3.1(iii) Page 1 Delaware The First State I, JEFFREY W. BULLOCK, SECRETARY OF STATE OF THE STATE OF DELAWARE DO HEREBY CERTIFY THAT THE ATTACHED IS A TRUE AND CORRECT COPY OF THE CERTIFICATE OF INCORPORATION OF ?LANTERN PHARMA INC.? FILED IN THIS OFFICE ON THE FIFTEENTH DAY OF JANUARY, A.D. 2020, AT 10:38 O`CLOCK A.M. A FILED COPY OF THIS CERTIFICATE HAS BEEN FORWARDED TO THE NEW CASTLE COU |
|
| April 16, 2020 |
Scott E. Bartel 633 West 5th Street, Suite 4000 Los Angeles, California 90071 [email protected] Direct: 213.358.6174 April 16, 2020 Ms. Sasha Parikh Ms. Vanessa Robertson Ms. Irene Paik Mr. Jeffrey Gabor Division of Corporation Finance Office of Life Sciences Securities and Exchange Commission 100 F Street, NE Washington, D.C. 20549 Re: Lantern Pharma Inc. Draft Registration Statement |
|
| April 16, 2020 |
Assignment Agreement dated as of January 5, 2018 with BioNumerik Pharmaceuticals, Inc. Exhibit 10.11 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (i) NOT MATERIAL AND (ii) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. CONFIDENTIAL ASSIGNMENT AGREEMENT THIS ASSIGNMENT AGREEMENT (the ?Agreement?) is made and entered into, as of the Effective Date, by and between Lantern Pharma, Inc. (hereinafter referred to a |
|
| April 16, 2020 |
Code of Business Conduct and Ethics Exhibit 14.1 LANTERN PHARMA INC. CODE OF BUSINESS CONDUCT AND ETHICS ADOPTED: October 15, 2019 1. Introduction. 1.1 The Board of Directors of Lantern Pharma Inc. (together with its subsidiaries, the ?Company?) has adopted this Code of Business Conduct and Ethics (the ?Code?) in order to: (a) promote honest and ethical conduct, including the ethical handling of actual or apparent conflicts of inter |
|
| April 16, 2020 |
Amended and Restated Voting Agreement Exhibit 10.6 Execution Version AMENDED AND RESTATED VOTING AGREEMENT TABLE OF CONTENTS Page 1. Voting Provisions Regarding Board of Directors 2 1.1 Size of the Board 2 1.2 Board Composition 2 1.3 Failure to Designate a Board Member 3 1.4 Removal of Board Members 3 1.5 No Liability for Election of Recommended Directors 4 1.6 No ?Bad Actor? Designees 4 2. Vote to Increase Authorized Common Stock 4 3 |
|
| April 16, 2020 |
Amended and Restated Investors’ Rights Agreement Exhibit 10.4 Execution Version AMENDED AND RESTATED INVESTORS? RIGHTS AGREEMENT TABLE OF CONTENTS Page 1. Definitions 1 2. Registration Rights 5 2.1 Demand Registration 5 2.2 Company Registration 6 2.3 Underwriting Requirements. 6 2.4 Obligations of the Company 8 2.5 Furnish Information 9 2.6 Expenses of Registration 9 2.7 Delay of Registration 10 2.8 Indemnification 10 2.9 Reports Under Exchange |
|
| April 16, 2020 |
Drug License and Development Agreement dated as of May 23, 2015 with Oncology Venture A/S Exhibit 10.8 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (i) NOT MATERIAL AND (ii) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. EXECUTION VERSION CONFIDENTIAL DRUG LICENSE AND DEVELOPMENT AGREEMENT by and between LANTERN PHARMA, INC. and ONCOLOGY VENTURE, APS EXECUTION VERSION CONFIDENTIAL DRUG LICENSE AND DEVELOPMENT A |
|
| April 16, 2020 |
Form of Indemnification Agreement Exhibit 10.3 INDEMNIFICATION AGREEMENT This Indemnification Agreement (?Agreement?), dated as of [DATE], is by and between Lantern Pharma Inc., a Delaware corporation (the ?Company?) and [NAME OF DIRECTOR/OFFICER] (the ?Indemnitee?). WHEREAS, Indemnitee is [a director/an officer] of the Company; WHEREAS, both the Company and Indemnitee recognize the increased risk of litigation and other claims be |
|
| April 16, 2020 |
Amended and Restated Right of First Refusal and Co-Sale Agreement Exhibit 10.5 Execution Version AMENDED AND RESTATED RIGHT OF FIRST REFUSAL AND CO-SALE AGREEMENT TABLE OF CONTENTS Page 1. Definitions 2 2. Agreement Among the Company, the Investors and the Stockholders of the Company 3 2.1 Right of First Refusal 3 2.2 Right of Co-Sale 5 2.3 Effect of Failure to Comply 7 3. Exempt Transfers 8 3.1 Exempted Transfers 8 3.2 Exempted Offerings 9 3.3 Prohibited Transf |
|
| April 16, 2020 |
Certificate of Conversion (Texas) Exhibit 3.1(i) Corporations Section P.O.Box 13697 Austin, Texas 78711-3697 Ruth R. Hughs Secretary of State Office of the Secretary of State CERTIFICATE OF CONVERSION The undersigned, as Secretary of State of Texas, hereby certifies that a filing instrument for Lantern Pharma Inc File Number: 801879299 Converting it to Lantern Pharma Inc. File Number: [Entity not of Record, Filing Number Not Avail |
|
| April 16, 2020 |
Exhibit 10.10 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (i) NOT MATERIAL AND (ii) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. EXECUTION VERSION AMENDMENT NO. 2 TO DRUG LICENSE AND DEVELOPMENT AGREEMENT This Amendment Number Two (?Amendment No. 2?), to the existing and in-force Drug License And Development Agreement ( |
|
| April 16, 2020 |
Technology License Agreement dated January 15, 2015, with AF Chemicals, LLC Exhibit 10.7 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (i) NOT MATERIAL AND (ii) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. TECHNOLOGY LICENSE AGREEMENT PARTIES This Technology License Agreement (the ?AGREEMENT?) is entered into by and between Lantern Pharma Inc., a Texas corporation (hereinafter referred to as ?LAN |
|
| April 16, 2020 |
Certificate of Conversion (Delaware) Exhibit 3.1(ii) Page 1 Delaware The First State I, JEFFREY W. BULLOCK, SECRETARY OF STATE OF THE STATE OF DELAWARE, DO HEREBY CERTIFY THE ATTACHED IS A TRUE AND CORRECT COPY OF THE CERTIFICATE OF CONVERSION OF A TEXAS CORPORATION UNDER THE NAME OF ?LANTERN PHARMA INC.? TO A DELAWARE CORPORATION, FILED IN THIS OFFICE ON THE FIFTEENTH DAY OF JANUARY, A.D. 2020, AT 10:38 O`CLOCK A.M. A FILED COPY OF |
|
| April 16, 2020 |
Addendum to Technology License Agreement dated February 8, 2016, with AF Chemicals, LLC Exhibit 10.12 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (i) NOT MATERIAL AND (ii) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. FINAL VERSION 2/8/15 CONFIDENTIAL ADDENDUM TO TECHNOLOGY LICENSE AGREEMENT by and between AF CHEMICALS LLC and LANTERN PHARMA, INC. FINAL VERSION 2/8/15 CONFIDENTIAL ADDENDUM TO TECHNOLOGY LIC |
|
| April 16, 2020 |
Exhibit 4.1(ii) THE SECURITIES REPRESENTED BY THIS WARRANT HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AND HAVE BEEN ACQUIRED FOR INVESTMENT AND NOT WITH A VIEW TO, OR IN CONNECTION WITH, THE SALE OR DISTRIBUTION THEREOF. NO SUCH SALE OR DISTRIBUTION MAY BE EFFECTED WITHOUT AN EFFECTIVE REGISTRATION STATEMENT RELATED THERETO OR AN OPINION OF COUNSEL IN A FORM REASONABLY SATISFACTORY |
|
| April 16, 2020 |
Power of Attorney (included on the signature page). As filed with the Securities and Exchange Commission on April 16, 2020 Registration No. |
|
| April 16, 2020 |
Amended and Restated 2018 Equity Incentive Plan Exhibit 10.1 AMENDED AND RESTATED LANTERN PHARMA INC. 2018 EQUITY INCENTIVE PLAN I. GENERAL PROVISIONS 1.1 Establishment. On August 29, 2018, the Board of Directors (?Board?) of Lantern Pharma Inc., a Texas corporation (?Corporation?) adopted the Lantern Pharma Inc. 2018 Equity Incentive Plan. The Lantern Pharma Inc. 2018 Equity Incentive Plan was approved by the Corporation?s shareholders on Augu |
|
| April 16, 2020 |
Exhibit 4.1(iii) THE SECURITIES REPRESENTED BY THIS WARRANT HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?), AND HAVE BEEN ACQUIRED FOR INVESTMENT AND NOT WITH A VIEW TO, OR IN CONNECTION WITH, THE SALE OR DISTRIBUTION THEREOF. NO SUCH SALE OR DISTRIBUTION MAY BE EFFECTED WITHOUT AN EFFECTIVE REGISTRATION STATEMENT RELATED THERETO OR AN OPINION OF COUNS |
|
| April 16, 2020 |
Exhibit 3.1(iv) BY-LAWS OF LANTERN PHARMA INC. ARTICLE I OFFICES Section 1.01 Registered Office. The registered office of Lantern Pharma Inc. (the ?Corporation?) will be fixed in the Certificate of Incorporation of the Corporation (the ?Certificate of Incorporation?). Section 1.02 Other Offices. The Corporation may have other offices, both within and without the State of Delaware, as the board of |
|
| April 16, 2020 |
Employment Agreement dated July 23, 2018 with Panna Sharma Exhibit 10.2 CONFIDENTIAL EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (this ?Agreement?), is made and entered into to be effective as of the 23rd day of July, 2018 (the ?Effective Date?), between Lantern Pharma Inc. (the ?Company?), and Panna Sharma (?Executive?). The Company and Executive may be referred to herein individually as a ?Party? or collectively as the ?Parties.? A. The Company belie |
|
| April 16, 2020 |
Exhibit 4.1(i) THE SECURITIES REPRESENTED BY THIS WARRANT HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AND HAVE BEEN ACQUIRED FOR INVESTMENT AND NOT WITH A VIEW TO, OR IN CONNECTION WITH, THE SALE OR DISTRIBUTION THEREOF. NO SUCH SALE OR DISTRIBUTION MAY BE EFFECTED WITHOUT AN EFFECTIVE REGISTRATION STATEMENT RELATED THERETO OR AN OPINION OF COUNSEL IN A FORM REASONABLY SATISFACTORY |
|
| April 16, 2020 |
Exhibit 21.1 List of Subsidiaries Name of Subsidiary Jurisdiction Lantern Pharma Limited Northern Ireland |
|
| January 24, 2020 |
Exhibit 10.3 INDEMNIFICATION AGREEMENT This Indemnification Agreement (?Agreement?), dated as of [DATE], is by and between Lantern Pharma Inc., a Delaware corporation (the ?Company?) and [NAME OF DIRECTOR/OFFICER] (the ?Indemnitee?). WHEREAS, Indemnitee is [a director/an officer] of the Company; WHEREAS, both the Company and Indemnitee recognize the increased risk of litigation and other claims be |
|
| January 24, 2020 |
AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT TABLE OF CONTENTS Exhibit 10.4 Execution Version AMENDED AND RESTATED INVESTORS? RIGHTS AGREEMENT TABLE OF CONTENTS Page 1. Definitions 1 2. Registration Rights 5 2.1 Demand Registration 5 2.2 Company Registration 6 2.3 Underwriting Requirements. 6 2.4 Obligations of the Company 8 2.5 Furnish Information 9 2.6 Expenses of Registration 9 2.7 Delay of Registration 10 2.8 Indemnification 10 2.9 Reports Under Exchange |
|
| January 24, 2020 |
DRUG LICENSE AND DEVELOPMENT AGREEMENT by and between LANTERN PHARMA, INC. ONCOLOGY VENTURE, APS Exhibit 10.8 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (i) NOT MATERIAL AND (ii) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. EXECUTION VERSION CONFIDENTIAL DRUG LICENSE AND DEVELOPMENT AGREEMENT by and between LANTERN PHARMA, INC. and ONCOLOGY VENTURE, APS EXECUTION VERSION CONFIDENTIAL DRUG LICENSE AND DEVELOPMENT A |
|
| January 24, 2020 |
LANTERN PHARMA INC. Preferred Stock Warrant Exhibit 4.1(iii) THE SECURITIES REPRESENTED BY THIS WARRANT HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?), AND HAVE BEEN ACQUIRED FOR INVESTMENT AND NOT WITH A VIEW TO, OR IN CONNECTION WITH, THE SALE OR DISTRIBUTION THEREOF. NO SUCH SALE OR DISTRIBUTION MAY BE EFFECTED WITHOUT AN EFFECTIVE REGISTRATION STATEMENT RELATED THERETO OR AN OPINION OF COUNS |
|
| January 24, 2020 |
Exhibit 10.2 CONFIDENTIAL EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (this ?Agreement?), is made and entered into to be effective as of the 23rd day of July, 2018 (the ?Effective Date?), between Lantern Pharma Inc. (the ?Company?), and Panna Sharma (?Executive?). The Company and Executive may be referred to herein individually as a ?Party? or collectively as the ?Parties.? A. The Company belie |
|
| January 24, 2020 |
Exhibit 10.9 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (i) NOT MATERIAL AND (ii) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. FINAL VERSION 2/8/16 CONFIDENTIAL ADDENDUM TO DRUG LICENSE AND DEVELOPMENT AGREEMENT by and between LANTERN PHARMA, INC. and ONCOLOGY VENTURE, APS FINAL VERSION 2/8/16 CONFIDENTIAL ADDENDUM TO |
|
| January 24, 2020 |
ADDENDUM TO TECHNOLOGY LICENSE AGREEMENT by and between AF CHEMICALS LLC LANTERN PHARMA, INC. EX-10.12 20 filename20.htm Exhibit 10.12 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (i) NOT MATERIAL AND (ii) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. FINAL VERSION 2/8/15 CONFIDENTIAL ADDENDUM TO TECHNOLOGY LICENSE AGREEMENT by and between AF CHEMICALS LLC and LANTERN PHARMA, INC. FINAL VERSION 2/8/15 CONFIDENTIAL |
|
| January 24, 2020 |
LANTERN PHARMA INC Preferred Stock Warrant Exhibit 4.1(ii) THE SECURITIES REPRESENTED BY THIS WARRANT HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AND HAVE BEEN ACQUIRED FOR INVESTMENT AND NOT WITH A VIEW TO, OR IN CONNECTION WITH, THE SALE OR DISTRIBUTION THEREOF. NO SUCH SALE OR DISTRIBUTION MAY BE EFFECTED WITHOUT AN EFFECTIVE REGISTRATION STATEMENT RELATED THERETO OR AN OPINION OF COUNSEL IN A FORM REASONABLY SATISFACTORY |
|
| January 24, 2020 |
AMENDED AND RESTATED VOTING AGREEMENT TABLE OF CONTENTS Exhibit 10.6 Execution Version AMENDED AND RESTATED VOTING AGREEMENT TABLE OF CONTENTS Page 1. Voting Provisions Regarding Board of Directors 2 1.1 Size of the Board 2 1.2 Board Composition 2 1.3 Failure to Designate a Board Member 3 1.4 Removal of Board Members 3 1.5 No Liability for Election of Recommended Directors 4 1.6 No ?Bad Actor? Designees 4 2. Vote to Increase Authorized Common Stock 4 3 |
|
| January 24, 2020 |
Exhibit 21.1 List of Subsidiaries Name of Subsidiary Jurisdiction Lantern Pharma Limited Northern Ireland |
|
| January 24, 2020 |
Exhibit 10.11 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (i) NOT MATERIAL AND (ii) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. CONFIDENTIAL ASSIGNMENT AGREEMENT THIS ASSIGNMENT AGREEMENT (the ?Agreement?) is made and entered into, as of the Effective Date, by and between Lantern Pharma, Inc. (hereinafter referred to a |
|
| January 24, 2020 |
AMENDMENT NO. 2 TO DRUG LICENSE AND DEVELOPMENT AGREEMENT Exhibit 10.10 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (i) NOT MATERIAL AND (ii) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. EXECUTION VERSION AMENDMENT NO. 2 TO DRUG LICENSE AND DEVELOPMENT AGREEMENT This Amendment Number Two (?Amendment No. 2?), to the existing and in-force Drug License And Development Agreement ( |
|
| January 24, 2020 |
AMENDED AND RESTATED RIGHT OF FIRST REFUSAL AND CO-SALE AGREEMENT TABLE OF CONTENTS Exhibit 10.5 Execution Version AMENDED AND RESTATED RIGHT OF FIRST REFUSAL AND CO-SALE AGREEMENT TABLE OF CONTENTS Page 1. Definitions 2 2. Agreement Among the Company, the Investors and the Stockholders of the Company 3 2.1 Right of First Refusal 3 2.2 Right of Co-Sale 5 2.3 Effect of Failure to Comply 7 3. Exempt Transfers 8 3.1 Exempted Transfers 8 3.2 Exempted Offerings 9 3.3 Prohibited Transf |
|
| January 24, 2020 |
As confidentially submitted to the Securities and Exchange Commission on January 24, 2020 This draft registration statement has not been publicly filed with the Securities and Exchange Commission and all information herein remains strictly confidential. |
|
| January 24, 2020 |
Office of the Secretary of State CERTIFICATE OF CONVERSION Exhibit 3.1(i) Corporations Section P.O.Box 13697 Austin, Texas 78711-3697 Ruth R. Hughs Secretary of State Office of the Secretary of State CERTIFICATE OF CONVERSION The undersigned, as Secretary of State of Texas, hereby certifies that a filing instrument for Lantern Pharma Inc File Number: 801879299 Converting it to Lantern Pharma Inc. File Number: [Entity not of Record, Filing Number Not Avail |
|
| January 24, 2020 |
Exhibit 3.1(iii) Page 1 Delaware The First State I, JEFFREY W. BULLOCK, SECRETARY OF STATE OF THE STATE OF DELAWARE DO HEREBY CERTIFY THAT THE ATTACHED IS A TRUE AND CORRECT COPY OF THE CERTIFICATE OF INCORPORATION OF ?LANTERN PHARMA INC.? FILED IN THIS OFFICE ON THE FIFTEENTH DAY OF JANUARY, A.D. 2020, AT 10:38 O`CLOCK A.M. A FILED COPY OF THIS CERTIFICATE HAS BEEN FORWARDED TO THE NEW CASTLE COU |
